English
简体中文
Total: £ 56.28
Published Date: 2025-10-17 | Pages: 117 | Tables: 125 | Medical Care
The global GMP-grade mRNA Production market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
GMP-grade mRNA Production refers to the manufacture of messenger RNA (mRNA) molecules under Good Manufacturing Practices (GMP) guidelines. This ensures the mRNA is produced in a controlled, consistent, and highly regulated environment, meeting the stringent quality standards required for pharmaceutical or clinical applications, such as mRNA-based vaccines or therapeutics.
From a downstream perspective, Vaccine Development accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
GMP-grade mRNA Production leading manufacturers including Kaneka, Takara Bio, Vernal Biosciences, Creative Biogene, GenScript Biotech Corporation, RiboPro, Biomay, Lonza, etc., dominate supply; the top five capture approximately % of global revenue, with Kaneka leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global GMP-grade mRNA Production market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Kaneka
Takara Bio
Vernal Biosciences
Creative Biogene
GenScript Biotech Corporation
RiboPro
Biomay
Lonza
Segment by Type
Design and Synthesis
Production
Quality Assurance
Others
Segment by Application
Vaccine Development
Drug Manufacturing
Technical Research
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the GMP-grade mRNA Production study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to GMP-grade mRNA Production: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global GMP-grade mRNA Production Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Design and Synthesis
1.2.3 Production
1.2.4 Quality Assurance
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global GMP-grade mRNA Production Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Vaccine Development
1.3.3 Drug Manufacturing
1.3.4 Technical Research
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global GMP-grade mRNA Production Revenue Estimates and Forecasts 2020-2031
2.2 Global GMP-grade mRNA Production Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global GMP-grade mRNA Production Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global GMP-grade mRNA Production Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Design and Synthesis Market Size by Players
3.3.2 Production Market Size by Players
3.3.3 Quality Assurance Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global GMP-grade mRNA Production Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global GMP-grade mRNA Production Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global GMP-grade mRNA Production Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America GMP-grade mRNA Production Market Size by Type (2020-2031)
6.4 North America GMP-grade mRNA Production Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America GMP-grade mRNA Production Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe GMP-grade mRNA Production Market Size by Type (2020-2031)
7.4 Europe GMP-grade mRNA Production Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe GMP-grade mRNA Production Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific GMP-grade mRNA Production Market Size by Type (2020-2031)
8.4 Asia-Pacific GMP-grade mRNA Production Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific GMP-grade mRNA Production Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America GMP-grade mRNA Production Market Size by Type (2020-2031)
9.4 Central and South America GMP-grade mRNA Production Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America GMP-grade mRNA Production Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa GMP-grade mRNA Production Market Size by Type (2020-2031)
10.4 Middle East and Africa GMP-grade mRNA Production Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa GMP-grade mRNA Production Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Kaneka
11.1.1 Kaneka Corporation Information
11.1.2 Kaneka Business Overview
11.1.3 Kaneka GMP-grade mRNA Production Product Features and Attributes
11.1.4 Kaneka GMP-grade mRNA Production Revenue and Gross Margin (2020-2025)
11.1.5 Kaneka GMP-grade mRNA Production Revenue by Product in 2024
11.1.6 Kaneka GMP-grade mRNA Production Revenue by Application in 2024
11.1.7 Kaneka GMP-grade mRNA Production Revenue by Geographic Area in 2024
11.1.8 Kaneka GMP-grade mRNA Production SWOT Analysis
11.1.9 Kaneka Recent Developments
11.2 Takara Bio
11.2.1 Takara Bio Corporation Information
11.2.2 Takara Bio Business Overview
11.2.3 Takara Bio GMP-grade mRNA Production Product Features and Attributes
11.2.4 Takara Bio GMP-grade mRNA Production Revenue and Gross Margin (2020-2025)
11.2.5 Takara Bio GMP-grade mRNA Production Revenue by Product in 2024
11.2.6 Takara Bio GMP-grade mRNA Production Revenue by Application in 2024
11.2.7 Takara Bio GMP-grade mRNA Production Revenue by Geographic Area in 2024
11.2.8 Takara Bio GMP-grade mRNA Production SWOT Analysis
11.2.9 Takara Bio Recent Developments
11.3 Vernal Biosciences
11.3.1 Vernal Biosciences Corporation Information
11.3.2 Vernal Biosciences Business Overview
11.3.3 Vernal Biosciences GMP-grade mRNA Production Product Features and Attributes
11.3.4 Vernal Biosciences GMP-grade mRNA Production Revenue and Gross Margin (2020-2025)
11.3.5 Vernal Biosciences GMP-grade mRNA Production Revenue by Product in 2024
11.3.6 Vernal Biosciences GMP-grade mRNA Production Revenue by Application in 2024
11.3.7 Vernal Biosciences GMP-grade mRNA Production Revenue by Geographic Area in 2024
11.3.8 Vernal Biosciences GMP-grade mRNA Production SWOT Analysis
11.3.9 Vernal Biosciences Recent Developments
11.4 Creative Biogene
11.4.1 Creative Biogene Corporation Information
11.4.2 Creative Biogene Business Overview
11.4.3 Creative Biogene GMP-grade mRNA Production Product Features and Attributes
11.4.4 Creative Biogene GMP-grade mRNA Production Revenue and Gross Margin (2020-2025)
11.4.5 Creative Biogene GMP-grade mRNA Production Revenue by Product in 2024
11.4.6 Creative Biogene GMP-grade mRNA Production Revenue by Application in 2024
11.4.7 Creative Biogene GMP-grade mRNA Production Revenue by Geographic Area in 2024
11.4.8 Creative Biogene GMP-grade mRNA Production SWOT Analysis
11.4.9 Creative Biogene Recent Developments
11.5 GenScript Biotech Corporation
11.5.1 GenScript Biotech Corporation Corporation Information
11.5.2 GenScript Biotech Corporation Business Overview
11.5.3 GenScript Biotech Corporation GMP-grade mRNA Production Product Features and Attributes
11.5.4 GenScript Biotech Corporation GMP-grade mRNA Production Revenue and Gross Margin (2020-2025)
11.5.5 GenScript Biotech Corporation GMP-grade mRNA Production Revenue by Product in 2024
11.5.6 GenScript Biotech Corporation GMP-grade mRNA Production Revenue by Application in 2024
11.5.7 GenScript Biotech Corporation GMP-grade mRNA Production Revenue by Geographic Area in 2024
11.5.8 GenScript Biotech Corporation GMP-grade mRNA Production SWOT Analysis
11.5.9 GenScript Biotech Corporation Recent Developments
11.6 RiboPro
11.6.1 RiboPro Corporation Information
11.6.2 RiboPro Business Overview
11.6.3 RiboPro GMP-grade mRNA Production Product Features and Attributes
11.6.4 RiboPro GMP-grade mRNA Production Revenue and Gross Margin (2020-2025)
11.6.5 RiboPro Recent Developments
11.7 Biomay
11.7.1 Biomay Corporation Information
11.7.2 Biomay Business Overview
11.7.3 Biomay GMP-grade mRNA Production Product Features and Attributes
11.7.4 Biomay GMP-grade mRNA Production Revenue and Gross Margin (2020-2025)
11.7.5 Biomay Recent Developments
11.8 Lonza
11.8.1 Lonza Corporation Information
11.8.2 Lonza Business Overview
11.8.3 Lonza GMP-grade mRNA Production Product Features and Attributes
11.8.4 Lonza GMP-grade mRNA Production Revenue and Gross Margin (2020-2025)
11.8.5 Lonza Recent Developments
12 GMP-grade mRNA ProductionIndustry Chain Analysis
12.1 GMP-grade mRNA Production Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 GMP-grade mRNA Production Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global GMP-grade mRNA Production Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global GMP-grade mRNA Production Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global GMP-grade mRNA Production Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global GMP-grade mRNA Production Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global GMP-grade mRNA Production Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global GMP-grade mRNA Production Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global GMP-grade mRNA Production Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global GMP-grade mRNA Production Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global GMP-grade mRNA Production by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GMP-grade mRNA Production as of 2024)
Table 11. Global GMP-grade mRNA Production Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global GMP-grade mRNA Production Companies Headquarters
Table 13. Global GMP-grade mRNA Production Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global GMP-grade mRNA Production Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global GMP-grade mRNA Production Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global GMP-grade mRNA Production Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global GMP-grade mRNA Production Revenue by Application (2026-2031) & (US$ Million)
Table 21. GMP-grade mRNA Production High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America GMP-grade mRNA Production Growth Accelerators and Market Barriers
Table 25. North America GMP-grade mRNA Production Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe GMP-grade mRNA Production Growth Accelerators and Market Barriers
Table 27. Europe GMP-grade mRNA Production Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific GMP-grade mRNA Production Growth Accelerators and Market Barriers
Table 29. Asia-Pacific GMP-grade mRNA Production Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America GMP-grade mRNA Production Investment Opportunities and Key Challenges
Table 31. Central and South America GMP-grade mRNA Production Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa GMP-grade mRNA Production Investment Opportunities and Key Challenges
Table 33. Middle East and Africa GMP-grade mRNA Production Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Kaneka Corporation Information
Table 35. Kaneka Description and Major Businesses
Table 36. Kaneka Product Features and Attributes
Table 37. Kaneka Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Kaneka Revenue Proportion by Product in 2024
Table 39. Kaneka Revenue Proportion by Application in 2024
Table 40. Kaneka Revenue Proportion by Geographic Area in 2024
Table 41. Kaneka GMP-grade mRNA Production SWOT Analysis
Table 42. Kaneka Recent Developments
Table 43. Takara Bio Corporation Information
Table 44. Takara Bio Description and Major Businesses
Table 45. Takara Bio Product Features and Attributes
Table 46. Takara Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Takara Bio Revenue Proportion by Product in 2024
Table 48. Takara Bio Revenue Proportion by Application in 2024
Table 49. Takara Bio Revenue Proportion by Geographic Area in 2024
Table 50. Takara Bio GMP-grade mRNA Production SWOT Analysis
Table 51. Takara Bio Recent Developments
Table 52. Vernal Biosciences Corporation Information
Table 53. Vernal Biosciences Description and Major Businesses
Table 54. Vernal Biosciences Product Features and Attributes
Table 55. Vernal Biosciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Vernal Biosciences Revenue Proportion by Product in 2024
Table 57. Vernal Biosciences Revenue Proportion by Application in 2024
Table 58. Vernal Biosciences Revenue Proportion by Geographic Area in 2024
Table 59. Vernal Biosciences GMP-grade mRNA Production SWOT Analysis
Table 60. Vernal Biosciences Recent Developments
Table 61. Creative Biogene Corporation Information
Table 62. Creative Biogene Description and Major Businesses
Table 63. Creative Biogene Product Features and Attributes
Table 64. Creative Biogene Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Creative Biogene Revenue Proportion by Product in 2024
Table 66. Creative Biogene Revenue Proportion by Application in 2024
Table 67. Creative Biogene Revenue Proportion by Geographic Area in 2024
Table 68. Creative Biogene GMP-grade mRNA Production SWOT Analysis
Table 69. Creative Biogene Recent Developments
Table 70. GenScript Biotech Corporation Corporation Information
Table 71. GenScript Biotech Corporation Description and Major Businesses
Table 72. GenScript Biotech Corporation Product Features and Attributes
Table 73. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. GenScript Biotech Corporation Revenue Proportion by Product in 2024
Table 75. GenScript Biotech Corporation Revenue Proportion by Application in 2024
Table 76. GenScript Biotech Corporation Revenue Proportion by Geographic Area in 2024
Table 77. GenScript Biotech Corporation GMP-grade mRNA Production SWOT Analysis
Table 78. GenScript Biotech Corporation Recent Developments
Table 79. RiboPro Corporation Information
Table 80. RiboPro Description and Major Businesses
Table 81. RiboPro Product Features and Attributes
Table 82. RiboPro Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. RiboPro Recent Developments
Table 84. Biomay Corporation Information
Table 85. Biomay Description and Major Businesses
Table 86. Biomay Product Features and Attributes
Table 87. Biomay Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Biomay Recent Developments
Table 89. Lonza Corporation Information
Table 90. Lonza Description and Major Businesses
Table 91. Lonza Product Features and Attributes
Table 92. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Lonza Recent Developments
Table 94. Raw Materials Key Suppliers
Table 95. Distributors List
Table 96. Market Trends and Market Evolution
Table 97. Market Drivers and Opportunities
Table 98. Market Challenges, Risks, and Restraints
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. GMP-grade mRNA Production Product Picture
Figure 2. Global GMP-grade mRNA Production Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Design and Synthesis Product Picture
Figure 4. Production Product Picture
Figure 5. Quality Assurance Product Picture
Figure 6. Others Product Picture
Figure 7. Global GMP-grade mRNA Production Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Vaccine Development
Figure 9. Drug Manufacturing
Figure 10. Technical Research
Figure 11. Others
Figure 12. GMP-grade mRNA Production Report Years Considered
Figure 13. Global GMP-grade mRNA Production Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 15. Global GMP-grade mRNA Production Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global GMP-grade mRNA Production Revenue Market Share by Region (2020-2031)
Figure 17. Global GMP-grade mRNA Production Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Design and Synthesis Revenue Market Share by Player in 2024
Figure 20. Production Revenue Market Share by Player in 2024
Figure 21. Quality Assurance Revenue Market Share by Player in 2024
Figure 22. Others Revenue Market Share by Player in 2024
Figure 23. Global GMP-grade mRNA Production Revenue Market Share by Type (2020-2031)
Figure 24. Global GMP-grade mRNA Production Revenue Market Share by Application (2020-2031)
Figure 25. North America GMP-grade mRNA Production Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players GMP-grade mRNA Production Revenue (US$ Million) in 2024
Figure 27. North America GMP-grade mRNA Production Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America GMP-grade mRNA Production Revenue (US$ Million) by Application (2020-2031)
Figure 29. US GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 30. Canada GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 32. Europe GMP-grade mRNA Production Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players GMP-grade mRNA Production Revenue (US$ Million) in 2024
Figure 34. Europe GMP-grade mRNA Production Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe GMP-grade mRNA Production Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 37. France GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 39. Italy GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 40. Russia GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific GMP-grade mRNA Production Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players GMP-grade mRNA Production Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific GMP-grade mRNA Production Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific GMP-grade mRNA Production Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 46. Japan GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 48. Australia GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 49. India GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore GMP-grade mRNA Production Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America GMP-grade mRNA Production Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players GMP-grade mRNA Production Revenue (US$ Million) in 2024
Figure 57. Central and South America GMP-grade mRNA Production Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America GMP-grade mRNA Production Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil GMP-grade mRNA Production Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina GMP-grade mRNA Production Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa GMP-grade mRNA Production Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players GMP-grade mRNA Production Revenue (US$ Million) in 2024
Figure 63. South America GMP-grade mRNA Production Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa GMP-grade mRNA Production Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries GMP-grade mRNA Production Revenue (2020-2025) & (US$ Million)
Figure 66. Israel GMP-grade mRNA Production Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt GMP-grade mRNA Production Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa GMP-grade mRNA Production Revenue (2020-2025) & (US$ Million)
Figure 69. GMP-grade mRNA Production Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
